In this article, we are going to look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market ...

Stifel head of biotech research Paul Matteis suggests looking for biotech names not dependent on the FDA while this sector ...

(The health of the CRISPR babies, three in all ... group has used base editing in utero to inactivate the hpd gene in monkeys by injecting the tool into the umbilical vein, providing entry ...

Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant ...

The CRISPR technology market is poised for explosive ... as tracked by Insider Monkey’s database of 900 hedge funds at the end of Q3 2024. At Insider Monkey, we are obsessed with the stocks ...

At Insider Monkey we are obsessed with the stocks that ... A laboratory cultivating cells for the development of gene and cell therapies. CRISPR Therapeutics AG (NASDAQ:CRSP) is focused on ...

Scientists have made a leap in genetic engineering by pushing elephant cells into an embryonic-like state. This marks a major step toward recreating traits of the extinct woolly mammoth, offering new ...

Another company looking to initiate clinical trials with an epigenetic-editor-based treatment for hepatitis is nChroma Bio.

This reduces the risk of persistent off-target effects that could arise from prolonged CRISPR activity. To really assess the potential of RIDE for treating HD in humans, the researchers needed to move ...

CRISPR Therapeutics won its first regulatory approval a little over a year ago, and has compelling candidates in the pipeline. Of course, Vertex's success didn't happen overnight -- and the ...

The medical promise of CRISPR gene editing can be seen most easily in current research on oral cancer, which affects more than 50,000 Americans every year. An increasing challenge in the treatment ...